공시 • Mar 12
Psyched Wellness Ltd. announced that it expects to receive CAD 1.719307 million in funding from Gotham Green Partners, LLC and affiliates and or co-investors of Gotham Green Psyched Wellness Ltd. announced that it has entered into a non-binding term sheet with returning investors Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. pursuant to which the Company shall complete a non-brokered private placement and will issue 170,228,410 common shares and common share purchase warrants for aggregate gross proceeds of up to CAD 1,719,306.941 on March 11, 2026. The Offering will be led by Gotham Green, and it may include affiliates and/or co-investors of Gotham Green. The company will raise proceeds in two tranches of up to CAD 859,653.47 each, subject to closing conditions. The Offering will consist of issuances of Common Shares at a price of CAD 0.0101 per Common Share and Warrants at a price of CAD 0.005 per Warrant. Each Warrant will entitle the holder thereof to acquire one additional Common Share at a price of CAD 0.0051 per Additional Share at any time on or before the Warrant expiry date, set sixty (60) months following the applicable closing date. The Company has obtained approval from the Canadian Securities Exchange (the "CSE") to issue the Common Shares and Warrants at a price lower than CAD 0.05 as the Offering Price is above the volume weighted average trading price of the Common Shares on the CSE for the 20 trading day period ending March 10, 2026. The Offering will be offered for purchase and sale to investors in the United States on a private placement basis. The initial tranche is scheduled to close on or about March 18, 2026 (the "Tranche 1 Closing Date") for aggregate gross proceeds of CAD 859,653.47 (the "Initial Tranche"). Subject to the policies of the CSE, closing of the second and final tranche could be for up to CAD 859,653.47 ("Tranche 2"). The Investor Group has no obligation to fund Tranche 2, and may elect to complete Tranche 2 in whole or in part or not at all in the Investor Group's sole discretion. Additionally, the closing of Tranche 2 shall be subject to satisfactory completion of due diligence in the Investor Group's sole discretion. All securities issued under the Offering will be subject to a four month and one day hold period from the applicable closing date and applicable legends as required pursuant to the U.S. Securities Act. Closing of the Offering is subject to customary closing conditions, including the approval of the CSE. 공시 • Nov 27
Psyched Wellness Ltd. Launches Calmer Psyched Wellness Ltd. announced the launch of Calmer, a new product offering that delivers twice the potency of its product, Calm. The Company has also enhanced the flavour profile of Calm in both the 30 ml and 60 ml formats, reducing the mushroom taste while maintaining potency and consumer experience. The launch coincides with Psyched's Black Friday promotion, offering customers a 40% discount site-wide (excluding merch) through December 1, 2025. 공시 • Apr 10
AME Wellness Inc. Working with its Advisors, Zerkalo LLC Completes an Initial Pilot Run of New Dietary Supplement in Form of 4 oz Shot Psyched Wellness Ltd. announced that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of new dietary supplement in form of a 4 oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3pl and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch. 공시 • Mar 04
Psyched Wellness Ltd., Annual General Meeting, May 15, 2025 Psyched Wellness Ltd., Annual General Meeting, May 15, 2025. 공시 • Nov 27
Psyched Wellness Ltd. Announces Resignation of Harrison Aaron as Director Psyched Wellness Ltd. announced that Harrison Aaron, a nominee of Gotham Green Partners, LLC ("Gotham Green"), has resigned as a director of the Company effective November 22, 2024. New Risk • Jul 31
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.69m (US$8.33m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Revenue is less than US$1m (CA$469k revenue, or US$339k). Market cap is less than US$10m (€7.69m market cap, or US$8.33m). 